Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">XBiotech discloses that it has been granted more time to submit its responses to the Day 180 List of Outstanding Issues by the CHMP in connection with the Marketing Authorization Application for Xilonix (11.12 -0.10)The Company was granted an additional 30 days to submit its responses, extending the «clock-stop» period to March 22, 2017. This extension will allow sufficient time for the Company to complete a pharmacokinetic study in healthy subjects. Data from this study is intended to generate additional time points for pk analysis. These findings are intended to address the relevant LoOIs and will be included in theCompany's response submission scheduled for March 22nd.</td> </tr></table>"